Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial. (Q38241985)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

title

Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

3

Laura Toppo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

2

Gianluca Tomasello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

5

Rodolfo Passalacqua

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Wanda Liguigli

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

1 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

1549-1557

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25145426 AND SRC:MED&resulttype=core&format=json

13 March 2020

cites work

Global cancer statistics

1 reference

Optimal chemotherapy for advanced gastric cancer: is there a global consensus?

21 January 2018

1 reference

Current questions for the treatment of advanced gastric cancer

21 January 2018

1 reference

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

21 January 2018

1 reference

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

21 January 2018

1 reference

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

Is there a role for second-line chemotherapy in advanced gastric cancer?

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

Molecular diagnosis for personalized target therapy in gastric cancer

21 January 2018

1 reference

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients

21 January 2018

1 reference

Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis

21 January 2018

1 reference

Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies

21 January 2018

1 reference

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

21 January 2018

1 reference

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

Genomic dysregulation in gastric tumors

21 January 2018

1 reference